

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Revumenib has demonstrated activity in patients with acute myeloid leukemia (AML) harboring alterations in which of the following genes?
 - a. KMT2A
 - b. NPM1
 - c. NUP98
 - d. All of the above
2. The Phase II KOMET-001 study of ziftomenib for patients with relapsed/refractory (R/R) NPM1-mutated AML reported which of the following durations of response?
 - a. 2.3 months
 - b. 4.6 months
 - c. 6.5 months
 - d. 8.3 months
3. The Phase II AUGMENT-101 study of revumenib for patients with R/R KMT2A-rearranged acute leukemia reported which of the following complete remission and complete remission with partial hematologic recovery rates?
 - a. 12%
 - b. 23%
 - c. 32%
 - d. 40%
4. A Phase Ib study of bleximenib in combination with intensive chemotherapy for newly diagnosed AML with KMT2A or NPM1 alterations evidenced what overall response rate across all patients?
 - a. 53%
 - b. 68%
 - c. 82%
 - d. 96%
5. In an ongoing study of enzomenib combined with azacitidine and venetoclax for R/R AML, what proportion of patients experienced Grade ≥ 3 differentiation syndrome?
 - a. 0%
 - b. 6%
 - c. 13%
 - d. 19%